TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18065335

Group type: EXPERIMENTAL
Intervention: 4.5 kg sandbag for 30 minutes with position change every hour
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: 2.3 kg sandbag for 2 hours with position change every hour
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: 4.5 kg sandbag for 30 minutes without position change
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: 2.3 kg sandbag for 2 hours without position change
Number of subjects: 169

Group type: COMPARATOR
Intervention: No sandbag and no position change (Control Group)
Number of subjects: 169
Study: 14965858

Group type: COMPARATOR
Intervention: Principal Component Analysis (PCA) applied on multichannel magnetocardiographic (MCG) recordings in patients with MI.
Number of subjects: 44

Group type: COMPARATOR
Intervention: Principal Component Analysis (PCA) applied on multichannel magnetocardiographic (MCG) recordings in patients with VT.
Number of subjects: 44

Group type: COMPARATOR
Intervention: Principal Component Analysis (PCA) applied on multichannel magnetocardiographic (MCG) recordings in normals.
Number of subjects: 44

Group type: COMPARATOR
Intervention: Principal Component Analysis (PCA) applied on multichannel magnetocardiographic (MCG) recordings in patients with CHD.
Number of subjects: 44
Study: 11001237

Group type: EXPERIMENTAL
Intervention: Fixed regimen of 30 mg mirtazapine at bedtime
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Ascending dose regimen of mirtazapine (15 mg to 30 mg at bedtime)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Both regimens (fixed and ascending dosing)
Number of subjects: 140
Study: 9071932

Group type: EXPERIMENTAL
Intervention: bFGF 0.1 mg twice daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg twice daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8326680

Group type: EXPERIMENTAL
Intervention: Ofloxacin (OFLX) for 5 days
Number of subjects: 110

Group type: COMPARATOR
Intervention: Ofloxacin (OFLX) for 10 days
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Ofloxacin (OFLX) for both groups
Number of subjects: 110
Study: 3098498

Group type: EXPERIMENTAL
Intervention: Levonorgestrel 20 mcg/day
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: TCu 380 Ag IUD
Number of subjects: 110
Study: 31129581

Group type: EXPERIMENTAL
Intervention: Strengths Model Case Management (SMCM)
Number of subjects: 210

Group type: COMPARATOR
Intervention: SMILE (control)
Number of subjects: 210
Study: 29912624

Group type: EXPERIMENTAL
Intervention: Graphic warning labels
Number of subjects: 0

Group type: COMPARATOR
Intervention: Text warning labels, calorie labels, and no labels
Number of subjects: 0
Study: 27825381

Group type: EXPERIMENTAL
Intervention: Cornerstone program (case management, trauma-focused cognitive behavioral therapy, mentoring/peer support, community-based practice, stigma and skill development)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 60
Study: 24911076

Group type: EXPERIMENTAL
Intervention: Biosimilar G-CSF (Zarzio(®), Sandoz Biopharmaceuticals)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Originator G-CSF (Neupogen(®), Amgen)
Number of subjects: 108
Study: 23158715

Group type: EXPERIMENTAL
Intervention: Oral endotracheal intubation (OEI)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Percutaneous dilatational tracheostomy (PDT)
Number of subjects: 61
Study: 19619073

Group type: COMPARATOR
Intervention: Rivastigmine (transdermal patch)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17178634

Group type: EXPERIMENTAL
Intervention: (R)-OXY
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: (R)-DEOB
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: (R)-OXY and (S)-OXY
Number of subjects: 0

Group type: COMPARATOR
Intervention: OXY
Number of subjects: 0
Study: 15711943

Group type: EXPERIMENTAL
Intervention: Electrostimulation voice exercise
Number of subjects: 24

Group type: COMPARATOR
Intervention: Traditional voice treatment
Number of subjects: 24
Study: 12161090

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 9449870

Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine 6 mg/kg
Number of subjects: 2534

Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine 6 mg/kg plus ivermectin 400 micrograms/kg
Number of subjects: 2534
Study: 7887382

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg/day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 2240629

Group type: EXPERIMENTAL
Intervention: Nitrous oxide (N2O)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Oxygen with isoflurane
Number of subjects: 70
Study: 360921

Group type: EXPERIMENTAL
Intervention: Active drug therapy (50 mg chlorthalidone, 100 mg chlorthalidone, and 100 mg chlorthalidone plus 0.25 mg reserpine)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study: 30921982

Group type: EXPERIMENTAL
Intervention: Th1-transforaminal epidural injection (Th1-TFEI)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Th1/2-parasagittal interlaminar epidural injection (Th1/2-pILEI)
Number of subjects: 30
Study: 28412762

Group type: EXPERIMENTAL
Intervention: Short sleep duration (<6.0 h)
Number of subjects: 981

Group type: EXPERIMENTAL
Intervention: Late bedtime (C1 vs. A1 and C2 vs. A2 or B2)
Number of subjects: 981
Study: 25843539

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 60
Study: 23499567

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle warm-up (IMW)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (IMWP)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 10
Study: 22221427

Group type: EXPERIMENTAL
Intervention: Formoterol 12 micrograms and Beclomethasone 200 micrograms (HFA; metered-dose inhaler) b.i.d. (FB)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Salmeterol 50 micrograms and Fluticasone 250 micrograms (dry-powder inhaler) b.i.d. (SF)
Number of subjects: 10
Study: 19224761

Group type: EXPERIMENTAL
Intervention: 6-mercaptopurine (6MP)/methotrexate (MTX) maintenance therapy
Number of subjects: 1614

Group type: EXPERIMENTAL
Intervention: Longer duration of oral 6MP/MTX maintenance therapy
Number of subjects: 1614

Group type: EXPERIMENTAL
Intervention: Presence of high hyperdiploidy
Number of subjects: 1614

Group type: EXPERIMENTAL
Intervention: TPMT activity measured in patients
Number of subjects: 1614

Group type: EXPERIMENTAL
Intervention: Average 6MP doses in TPMT wild-type patients
Number of subjects: 1614
Study: 17301297

Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone, 30 mg per kilogram of body weight
Number of subjects: 199

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study: 16265829

Group type: COMPARATOR
Intervention: Conventional treatment (oral and intravenous fluid replacement, NSAIDs, caffeine)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Epidural blood patch (EBP)
Number of subjects: 32
Study: 11591613

Group type: COMPARATOR
Intervention: CEE 0.625 mg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: CEE 0.625 mg and MPA 2.5 mg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: CEE 0.625 mg and MPA 5.0 mg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 45
Study: 9574878

Group type: EXPERIMENTAL
Intervention: Budesonide (200 microg b.i.d.; n = 16)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Levocabastine (200 microg b.i.d.; n = 16)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (n = 12)
Number of subjects: 44
Study: 7875113

Group type: EXPERIMENTAL
Intervention: Bilateral electroconvulsive therapy (ECT)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Unilateral electroconvulsive therapy (ECT)
Number of subjects: 9
Study: 3213920

Group type: EXPERIMENTAL
Intervention: General anaesthesia plus retrobulbar block
Number of subjects: 28

Group type: COMPARATOR
Intervention: General anaesthesia alone
Number of subjects: 28
Study: 29850915

Group type: EXPERIMENTAL
Intervention: disease-specific manualized CBT (PASCET-PI) plus standard medical care (CAU)
Number of subjects: 70

Group type: COMPARATOR
Intervention: standard medical care (CAU)
Number of subjects: 70
Study: 26530153

Group type: EXPERIMENTAL
Intervention: Sleep deprivation with nocturnal light exposure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sleep deprivation under dark conditions
Number of subjects: 0
Study: 24838360

Group type: EXPERIMENTAL
Intervention: Long detection setting (30 of 40 intervals)
Number of subjects: 477

Group type: COMPARATOR
Intervention: Nominal setting (18 of 24 intervals)
Number of subjects: 477
Study: 23564755

Group type: EXPERIMENTAL
Intervention: Saxagliptin
Number of subjects: 16496

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16496
Study: 19783808

Group type: EXPERIMENTAL
Intervention: High behavior modification
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low behavior modification
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medication manipulation
Number of subjects: 0
Study: 18684808

Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 16140028

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA) inhalation (3 ml 0.1% in PBS)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo inhalation (3 ml PBS)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA) inhalation
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo inhalation
Number of subjects: 16
Study: 12777432

Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Post-mortem questionnaire
Number of subjects: 1000

Group type: COMPARATOR
Intervention: All-cause mortality
Number of subjects: 1000
Study: 11404653

Group type: EXPERIMENTAL
Intervention: Salbutamol by Diskus
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Salbutamol by pMDI
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 9363868

Group type: EXPERIMENTAL
Intervention: rhIL‐11 (50 microg/kg/d)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: rhIL‐11
Number of subjects: 77
Study: 1306735

Group type: EXPERIMENTAL
Intervention: 200 mg 4-HPR daily for 52 weeks
Number of subjects: 115

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 115
Study: 2986901

Group type: EXPERIMENTAL
Intervention: Enalapril therapy
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31970796

Group type: EXPERIMENTAL
Intervention: Whole blood treatment
Number of subjects: 15

Group type: COMPARATOR
Intervention: Component therapy (current standard of care)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Relative risk of whole blood compared to component therapy
Number of subjects: 15
Study: 30663629

Group type: EXPERIMENTAL
Intervention: Outpatient individual treatment adherence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standardized admission assessment with the European Addiction Severity Index (EuropASI)
Number of subjects: 0
Study: 29265999

Group type: EXPERIMENTAL
Intervention: Mam-Kind intervention
Number of subjects: 70
Study: 26190381

Group type: EXPERIMENTAL
Intervention: Alcohol handrub (covering all hand surfaces in no particular order)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alcohol handrub (using the 7-step technique)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlorhexidine handwashing
Number of subjects: 0
Study: 23318877

Group type: EXPERIMENTAL
Intervention: Exercise training for 16 weeks
Number of subjects: 11

Group type: COMPARATOR
Intervention: Women with PCOS
Number of subjects: 11
Study: 20835747

Group type: EXPERIMENTAL
Intervention: Hypertension (blood pressure levels)
Number of subjects: 82037

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 82037
Study: 20021654

Group type: EXPERIMENTAL
Intervention: IUI COH (Intrauterine Insemination with Controlled Ovarian Hyperstimulation)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: IVF e SET (IVF elective Single Embryo Transfer)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: MNC IVF (Modified Natural Cycle IVF)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 600
Study: 16754834

Group type: EXPERIMENTAL
Intervention: Low-dose ketamine (100 ng/mL of plasma)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: High-dose ketamine (200 ng/mL of plasma)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 12887574

Group type: EXPERIMENTAL
Intervention: Modified Triad VLC resin
Number of subjects: 35

Group type: COMPARATOR
Intervention: Transbond XT resin
Number of subjects: 35
Study: 10501150

Group type: EXPERIMENTAL
Intervention: Continuous and all-night exposure to noise at 45 dBA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intermittent noise exposure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Silent environment
Number of subjects: 0
Study: 9198430

Group type: EXPERIMENTAL
Intervention: Modified Retroplast with ytterbium trifluoride
Number of subjects: 351

Group type: COMPARATOR
Intervention: Silver-containing Retroplast
Number of subjects: 351
Study: 1672841

Group type: EXPERIMENTAL
Intervention: Antianginal drugs (beta-blockers, calcium antagonists, nitrates, alone or in various combinations)
Number of subjects: 57
Study: 7031853

Group type: EXPERIMENTAL
Intervention: Tinidazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6439699

Group type: EXPERIMENTAL
Intervention: Mixed beam radiation therapy
Number of subjects: 322

Group type: COMPARATOR
Intervention: Photon radiation therapy
Number of subjects: 322
Study: 29714435

Group type: EXPERIMENTAL
Intervention: Glycerol
Number of subjects: 50

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 50
Study: 28033254

Group type: EXPERIMENTAL
Intervention: Early home-based cardiac rehabilitation program
Number of subjects: 52

Group type: COMPARATOR
Intervention: Usual care (Control group)
Number of subjects: 52
Study: 25117997

Group type: EXPERIMENTAL
Intervention: 600 IU D2 from UVB-treated mushrooms
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 4000 IU D2 from UVB-treated mushrooms
Number of subjects: 43

Group type: COMPARATOR
Intervention: 600 IU D3 from untreated mushrooms
Number of subjects: 43

Group type: COMPARATOR
Intervention: 4000 IU D3 from untreated mushrooms
Number of subjects: 43
Study: 22772335

Group type: EXPERIMENTAL
Intervention: Dopamine D₃ receptor antagonist, GSK598809 (175 mg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 20046182

Group type: EXPERIMENTAL
Intervention: 18F‐fluorodeoxyglucose (FDG) PET imaging during exercise
Number of subjects: 0
Study: 18330846

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG) monotherapy, mean maintenance dose 217.2 mg/day
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG) monotherapy
Number of subjects: 446
Study: 15983308

Group type: EXPERIMENTAL
Intervention: Multisystemic therapy (MST) for approximately 6 months
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Multisystemic therapy (MST)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 127
Study: 12671340

Group type: EXPERIMENTAL
Intervention: Implantable defibrillators
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amiodarone and dofetilide
Number of subjects: 0
Study: 10408847

Group type: EXPERIMENTAL
Intervention: Granisetron 3 mg intravenous
Number of subjects: 223

Group type: COMPARATOR
Intervention: Prednisolone 25 mg oral plus metopimazine 30 mg oral
Number of subjects: 223
Study: 8877895

Group type: EXPERIMENTAL
Intervention: Menatetrenone (15 mg) after meal A (8.8 g fat)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Menatetrenone (15 mg) after meal B (20.0 g fat)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Menatetrenone (15 mg) after meal C (34.9 g fat)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Menatetrenone (15 mg) after meal B (20.0 g fat) without lunch
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Menatetrenone (15 mg) after meal D (53.8 g fat)
Number of subjects: 18
Study: 1892404

Group type: EXPERIMENTAL
Intervention: Systemic antibiotics from immediately after surgery until the third day (Group B)
Number of subjects: 2165

Group type: EXPERIMENTAL
Intervention: Local sterile antibiotic powder sprinkled into the wound during surgery (Group C)
Number of subjects: 2165

Group type: EXPERIMENTAL
Intervention: Systemic antibiotics from 2 days before surgery until the second day after surgery (Group D)
Number of subjects: 2165

Group type: COMPARATOR
Intervention: No antibiotics (Group A)
Number of subjects: 2165
Study: 6135828

Group type: EXPERIMENTAL
Intervention: Exclusion diets and double-blind food provocation
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Independent psychiatric examination
Number of subjects: 27
Study: 30866108

Group type: EXPERIMENTAL
Intervention: Detomidine (0.01 mg/kg bwt)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Detomidine (0.01 mg/kg bwt) + Butorphanol (0.02 mg/kg bwt)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline (0.9% solution, 10 mL)
Number of subjects: 6
Study: 28604151

Group type: EXPERIMENTAL
Intervention: Diltiazem-Hydrochloride (DTZ) in sustained-release matrix tablets
Number of subjects: 8

Group type: COMPARATOR
Intervention: Reference product
Number of subjects: 8
Study: 27214088

Group type: EXPERIMENTAL
Intervention: Eprosartan (3 and 10 μg/kg/min for 15 min per dose)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Eprosartan (3 and 10 μg/kg/min for 15 min per dose) with low sodium diet
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Eprosartan (3 and 10 μg/kg/min for 15 min per dose) with Ang II co-infusion (1 ng/kg/min)
Number of subjects: 73
Study: 25075176

Group type: EXPERIMENTAL
Intervention: Lidocaine 2% (5 mL) delivered by JetPeel™‐3 followed by multiple injections of BTX‐A (100 units)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lidocaine 2% (5 mL) and BTX‐A (50 units) delivered together by JetPeel™‐3
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lidocaine delivered by JetPeel™‐3 followed by multiple BTX‐A injections
Number of subjects: 20
Study: 22748624

Group type: EXPERIMENTAL
Intervention: Thiomersal-containing process (Group TC)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Thiomersal-free process (Group TF)
Number of subjects: 320
Study: 20185655

Group type: EXPERIMENTAL
Intervention: CARDEAN
Number of subjects: 159

Group type: COMPARATOR
Intervention: Control
Number of subjects: 159
Study: 18035201

Group type: EXPERIMENTAL
Intervention: Lamotrigine (400 mg daily, titrated over 8 weeks)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 16282256

Group type: EXPERIMENTAL
Intervention: START program (short-term acute residential treatment)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Inpatient unit at a Department of Veterans Affairs (VA) hospital
Number of subjects: 99
Study: 12580657

Group type: EXPERIMENTAL
Intervention: Plyometric training
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no plyometric training)
Number of subjects: 18
Study: 10070128

Group type: EXPERIMENTAL
Intervention: Urodilatin 5 ng. kg‐1. min‐1
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Urodilatin 10 ng. kg‐1. min‐1
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Urodilatin 20 ng. kg‐1. min‐1
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Urodilatin 40 ng. kg‐1. min‐1
Number of subjects: 8
Study: 7718463

Group type: EXPERIMENTAL
Intervention: 2% ketoconazole shampoo (twice weekly for 2-4 weeks)
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: 2% ketoconazole shampoo (once-weekly, once every other week, alternating with placebo)
Number of subjects: 575

Group type: COMPARATOR
Intervention: Placebo shampoo (once-weekly)
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Active/placebo group (alternating treatment)
Number of subjects: 575
Study: 2044721

Group type: EXPERIMENTAL
Intervention: Carbonyl iron
Number of subjects: 49

Group type: COMPARATOR
Intervention: Ferrous sulfate
Number of subjects: 49
Study: 6112386

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid plus dipyridamole (1050 mg + 150 mg/day, group A)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (1200 mg/day, group B)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 66
Study: 31390223

Group type: EXPERIMENTAL
Intervention: Care pathway (CP) implemented in 31 teams
Number of subjects: 56

Group type: COMPARATOR
Intervention: Usual care in 25 teams
Number of subjects: 56
Study: 28006059

Group type: EXPERIMENTAL
Intervention: Cetuximab with radiotherapy and cisplatin
Number of subjects: 891
Study: 26338693

Group type: EXPERIMENTAL
Intervention: Aripiprazole (5‐30 mg/d)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Risperidone (1‐6 mg/d)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 198

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 198
Study: 23672956

Group type: EXPERIMENTAL
Intervention: Subcutaneous hydrocortisone (100 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intramuscular hydrocortisone (100 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sodium chloride (0.9%)
Number of subjects: 12
Study: 21904103

Group type: EXPERIMENTAL
Intervention: MR-FV group (behavioral intervention with meal replacements, fruits, and vegetables)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (usual-care weight-loss counseling)
Number of subjects: 38
Study: 19434784

Group type: EXPERIMENTAL
Intervention: Topical provocation with 15 mg GSTS
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control provocation
Number of subjects: 24
Study: 16753016

Group type: EXPERIMENTAL
Intervention: Teriparatide 20 or 40 microg
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 15107771

Group type: EXPERIMENTAL
Intervention: Onlay autogenous bone graft from the mandibular/chin area
Number of subjects: 20